GlassScriptPhysician profile
Jean-Pierre Andre Blaize
NPI 1700269404
$8,733.48
in general payments reported to CMS, 2019-2025
63 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $118 · 2021: $611 · 2022: $4,882 · 2023: $2,304 · 2024: $130 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,594 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,594.25 |
| Education | $194.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $586.53 | 2021-2025 | |
| Janssen Biotech, INC. | $557.34 | 2020-2025 | Erleada, Rybrevant, Tremfya |
| Merck Sharp & Dohme LLC | $537.17 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $500.05 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Taiho Oncology, INC. | $487.69 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $445.87 | 2021-2023 | Lynparza, Tagrisso, Calquence |
| E.R. Squibb & Sons, L.L.C. | $375.60 | 2022-2025 | Opdualag, Opdivo |
| Genentech USA, INC. | $355.92 | 2021-2023 | Tecentriq, Alecensa, Gavreto |
| Genzyme Corporation | $290.88 | 2022-2023 | |
| Daiichi Sankyo INC. | $279.35 | 2021-2025 | Enhertu, Injectafer, Vanflyta |
| Celgene Corporation | $273.94 | 2021-2023 | Pomalyst, Reblozyl |
| Incyte Corporation | $273.57 | 2021-2023 | Pemazyre, Monjuvi, Jakafi |
| Lilly USA, LLC | $264.23 | 2019-2023 | Jaypirca, Verzenio |
| Eisai INC. | $235.63 | 2021-2025 | |
| Pfizer INC. | $232.81 | 2022-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean-Pierre Blaize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.